28.02.2019 – 17:08
Posterior and Right Ventricular Myocardial Infarction Detection - CardioSecur® Shines a Light on the Dark Side of the Moon
- Press_Release_Posterior and Right Ventricular Myocardial Infarction Detection .pdf
PDF - 580 kB
PDF - 364 kB
Up to 57 % STEMI cases are not visible on a 12-lead-ECG. This is why the European Society of Cardiology and the American Heart Association (AHA) recommend recording additional leads to detect posterior and inferior infarcts. CardioSecur with 22-leads and 4 electrodes is currently the only ECG that implements these guidelines without reattaching electrodes.
Frankfurt, February 2019. When a myocardial infarction is suspected, but the 12-lead ECG is inconclusive, the guidelines of the European Society of Cardiology recommend the recording of additional leads (V7-V9, VR3-VR4). This recommendation is shared by the American Heart Association (AHA), which already advocated for expanded lead systems in 2009. The American Heart Association also called for ECG machines that are "programmed to suggest the recording of right-sided chest leads V3R and V4R when ST elevation is greater than 0.1 mV occurs in leads II, III, and aVF." [Moreover, they also called for "ECG manufacturers [...] to develop software capable of displaying the spatial orientation of the ST-segment in both the frontal and transverse planes" and to provide "algorithms [that] should refer to the occluded vessel and to the site of the occlusions within that vessel."
The reasons for this are due to the fact that the diagnosis of posterior myocardial infarctions is still considered to be the "dark side of the moon" of ECG interpretation.[v] Almost half of all posterior myocardial infarction cases are not detected by conventional 12-lead ECGs. If lateral leads (12 +V7-V9) are applied, then the accuracy of the diagnosis increases significantly. Studies have found that up to 57 % of STEMI cases could be detected with the use of additional leads.
CardioSecur is the only ECG that implements the guidelines of the European Society of Cardiology and the recommendations of the AHA into practice, without the need to reattach electrodes. CardioSecur offers physicians a 360° view of the heart with a 22-lead clinical-quality ECG (12-leads + V7-V9, VR3-VR9) that uses only four electrodes. It gives medical professionals the opportunity to explore new diagnostic dimensions and detect anterior, lateral, inferior and posterior wall infarctions in one measurement. Which in turn allows for immediate reperfusion therapy and reduces morbidity and mortality. The significant advantage of CardioSecur in detecting posterior myocardial infarctions compared to conventional 12-lead ECG systems has been proven again in a recent clinical trial in which it was used in ambulances. With CardioSecur physicians are finally able to explore the dark side of the moon.
Additional information at www.mobile-ecg.com
Personal MedSystems GmbH develops and sells ECG systems and services for private users and healthcare professionals under the name CardioSecur. CardioSecur Active is an innovative, 15-lead, clinical-grade ECG for personal use. In a few seconds, it generates personalized feedback regarding changes in the heart's health and provides a simple recommendation to act regarding whether to see a doctor or not. The entire system consists of a 50g light cable with four electrodes, the complimentary CardioSecur Active App and the user's smartphone or tablet. CardioSecur Pro is the mobile, clinical ECG solution for physicians and medical professionals. CardioSecur Pro operates based upon guidelines from the European Society of Cardiology by providing 22 leads, making a 360° view of the heart possible. It is the only system that thereby recognizes infarctions of the anterior, lateral and posterior walls of the heart. Press contact: Personal MedSystems GmbH Eduard Lerperger Phone +49 (0) 151-19120692 email@example.com